SEARCH

SEARCH BY CITATION

References

  • 1
    Berry SJ, Coffey DS, Walsh PC, Ewing LL. The development of human benign prostatic hyperplasia with age. J Urol 1984; 132: 4749.
  • 2
    Parker SL, Tong T, Dalden S, Wingo PA. Cancer Statistics, 1995. CA, Cancer J Clinicians 1996; 46: 528.
  • 3
    Coffey DS. The molecular biology, endocrinology, and physiology of the prostate and seminal vesicles. In Walsh PC et al., eds, Campbell's Urology 6th edn, Philadelphia: WB Saunders, 1992: 22166.
  • 4
    Cunha GR, Chung LWK, Shannon JM, Taguchi O, Fuji H. Hormone-induced morphogenesis and growth. Role of mesenchymal epithelial interactions. Recent Prog Horm Res 1983; 39: 55998.
  • 5
    McNeal JE. The prostate and prostatic urethra: A morphological synthesis. J Urol 1972; 107: 100816.
  • 6
    McNeal JE. Pathology of benign prostatic hyperplasia: Insight into etiology. Urol Clin N Am 1990; 17: 47786.
  • 7
    McNeal JE. Normal histology of the prostate. Am J Surg Pathol 1988; 12: 61933.
  • 8
    Isaacs JT, Coffey DS. Etiology and disease processes of benign prostatic hyperplasia. Prostate 1989; 2 (Suppl): 3350.
  • 9
    Siitieri PK, MacDonald PG. Role of extraglandular estrogen in human endocrinology. In Greep RO, Astwood EB, eds, Handbook of Physiology, Sect. 7, Endocrinology, Vol II. Baltimore: Williams & Wilkins, 1973: 51529.
  • 10
    Trachtenberg J, Hicks LL, Walsh PC. Androgen and estrogen receptor content in spontaneous and experimentally induced canine prostatic hyperplasia. J Clin Invest 1980; 65: 10519.
  • 11
    Prins GS, Birch L, Greene GL. Androgen receptor localization in different cell types of the adult rat prostate. Endocrinology 1991; 129: 318799.
  • 12
    George FW, Russell DW, Wilson JD. Feed-forward control of prostate growth: dihydrotestosterone induces expression of its own biosynthetic enzyme, steroid 5-α-reductase. Proc Nat Acad Sci USA 1991; 88: 80448.
  • 13
    Shannon JM, Cunha GR. Autoradiographic localization of androgen binding in the developing mouse prostate. Prostate 1983; 4: 33773.
  • 14
    Peters CA, Barrack ER. A new method for labelling and autoradiographic localization of androgen receptors. J Histochem Cytochem 1987; 35: 75562.
  • 15
    Thompson TC, Timme TL, Hall SJ, Stapleton AMF. Perspectives on the molecular biology of prostate cancer. In Vogelzang NJ et al., eds, Comprehensive Textbook of Genitourinary Oncology. Baltimore: Williams & Wilkins, 1995: 58399.
  • 16
    Thompson TC. Growth factors and oncogenes in prostate cancer. Cancer Cells 1990; 2: 34554.
  • 17
    Marton R, Issacs J, Isaacs W. Differential effects of growth factor antagonists on neoplastic and normal prostatic cells. Prostate 1990; 17: 32736.
  • 18
    Yan G, Fukabori Y, McBride G et al. Exon switching and activation of stromal and embryonic fibroblast growth factor (FGF)-FGF receptor genes in prostate epithelial cells accompany stromal independence and malignancy. Mol Cell Biol 1993; 13: 451322.
  • 19
    Steiner MS, Barrack ER. Transforming growth factor-β1 overproduction in prostate cancer: Effects on growth in vivo and in vitro. Mol Endocrinol 1992; 5: 1525.
  • 20
    Takeichi M. Cadherin cell adhesion receptors as a morphogenetic regulator (review). Science 1991; 251: 14515.
  • 21
    Yan G, Fukabori Y, Nikolaropoulos S, Wang F, McKeehan WL. Heparin-binding keratinocyte growth factor is a candidate of stromal to epithelial cell andromedin. Mol Endocrinol 1992; 6: 21238.
  • 22
    Abrahamsson PA, Falkner S, Falt K, Grimelius L. The course of neuroendocrine differentiation in prostatic carcinomas: An immunohistochemical study testing chromogranin A as an ‘endocrine marker’. Pathol Res Pract 1989; 185: 37380.
  • 23
    Di Sant'Agnese PA. Neuroendocrine differentiation in carcinoma of the prostate. Cancer 1992; 70 (suppl): 25468.
  • 24
    Cahen RJ, Glezerson G, Hafferjee Z. Prostatic carcinoma: Histological and immunohistological factors affecting prognosis. Br J Urol 1990; 66: 40510.
  • 25
    Sehgal I, Bailey J, Hitzemann K et al. Epidermal growth factor receptor-dependent stimulation of amphiregulin expression in androgen-stimulated human prostate cancer cells. Mol Biol Cell 1994; 5: 33947.
  • 26
    MacDonald PC. Origin of estrogen in men. In Grayhack JT et al., eds, Benign prostatic hyperplasia. Workshop proceedings, NIAMDD, US Government Printing Office, 1976: 1912.
  • 27
    Trachtenberg J, Hicks LL, Walsh PC. Methods for the determination of androgen receptor concentration in human prostatic tissue. Invest Urol 1981; 18: 34955.
  • 28
    Labrie F, Belanger A, Simard J et al. Combination therapy for prostate cancer. Endocrine and biologic basis of its choice as new standard first-line therapy. Cancer 1993; 71 (Suppl): 105967.
  • 29
    Pavone-Macaluso M, De Voogt HJ, Viggiano G et al. Comparison of diethylstilbestrol, cyproterone acetate and medroxyprogesterone acetate in the treatment of advanced prostate cancer: Final analysis of a randomised phase III trial of the EORTC. J Urol 1986; 136: 62431.
  • 30
    Goldenberg SL, Bruchovsky N, Rennie PS et al. The combination of cyproterone acetate and low-dose diethylstilbestrol on the treatment of advanced prostatic carcinoma. J Urol 1988; 140: 14605.
  • 31
    MaCleod PG, Benson RC Jr, Eisenberg MA et al. The use of flutamide in hormone refractory metastatic prostate cancer. Cancer 1993; 72 (Suppl): 38703.
  • 32
    Bailar JC, Byar DP, VACURG Estrogen treatment for cancer of the prostate: Early results with 3 doses of diethylstilbestrol and placebo. Cancer 1970; 26: 25761.
  • 33
    Labrie F, Dupont A, Belanger A et al. New approach in the treatment of prostate cancer: Complete instead of partial withdrawal of androgens. Prostate 1983; 4: 57994.
  • 34
    Crawford ED, Eisenberger MA, McCleod DG et al. A controlled trial of leuroprolide with and without flutamide in prostatic carcinoma. N Engl J Med 1989; 321: 41924.
  • 35
    Denis L, Murphy GP. Overview of phase III trials in combined androgen treatment in patients with metastatic prostate cancer. Cancer 1993; 72: 388895.
  • 36
    Zetter BR. The cellular basis of site-specific metastasis. N Eng J Med 1990; 322: 60512.
  • 37
    Tannock IF. Principles of cell proliferation: Cell kinetics. In De Vita VT Jr et al., eds, Cancer: Principles and Practice of Oncology. Philadelphia: JB Lippincott, 1989: 313.
  • 38
    Schroder FH. Hormonal therapy for prostate cancer. In Lepor H, Lawson R, eds, Prostate Diseases. Philadelphia: WB Saunders, 1993: 34763.
  • 39
    Suzuki M, Sata N, Watanabe Y et al. Androgen receptor gene mutations in human prostate cancer. J Steroid Biochem Mol Biol 1993; 46: 75965.
  • 40
    Roberts AB, Sporn MB. Transforming growth factor-α. Adv Cancer Res 1988; 57: 10745.
  • 41
    Miyashita T, Krajewski S, Krajewski M et al. Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene 1994; 9: 17991805.
  • 42
    Colombel M, Gil S, O'Toole KM et al. Detection of the apoptosis-suppressing oncoprotein bcl-2 in hormone-refractory human prostate cancer. Am J Pathol 1993; 143: 390400.
  • 43
    Dawson NA, Trepel J. Management of hormone-refractory prostate cancer: Chemotherapy and newer approaches. In Vogelzang NJ et al. eds, Comprehensive Textbook of Genitourinary Oncology. Baltimore: Williams & Wilkins, 1996: 90713.
  • 44
    Skowronski RJ, Peehl DM, Feldman D. Vitamin D and prostate cancer: 1–25- dihydroxyvitamin D3 receptors and actions in human prostate cancer cell lines. Endocrinology 1993; 13: 195260.
  • 45
    Myers C, Cooper M, Stein C et al. Suramin: A novel growth factor antagonist with activity in hormone-refractory metastatic prostate cancer. J Clin Oncol 1992; 10: 8819.
  • 46
    Stein CA. Suramin: A novel antineoplastic agent with multiple potential mechanisms of action. Cancer Res 1993; 53: 223948.
  • 47
    Sklar GN, Eddy HA, Jacobs SC, Kyprianou N. Combined antitumor effect of suramin plus irradiation in human prostate cancer cells: The role of apoptosis. J Urol 1993; 150: 152632.
  • 48
    Kadmon D, Thompson TC. Chemoprevention in prostate cancer. In Vogelzang NJ et al., eds, Comprehensive Textbook of Genitourinary Oncology. Baltimore: Williams & Wilkins, 1996: 65767.
  • 49
    Kelloff GJ, Boone W, Crowell JA et al. Chemopreventive drug development: Perspectives and progress. Cancer Epidem Biomarkers Prev 1994; 3: 8598.